TransMedics Group Inc vs Williams-Sonoma, Inc. — how do they compare? TransMedics Group Inc trades at $78.15 (market cap $2.74B), while Williams-Sonoma, Inc. trades at $241.16 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 10.3× TransMedics Group Inc's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Williams-Sonoma, Inc. for 59 Days on average.
| TMDX | WSM | |
|---|---|---|
Market Cap | $2.74B | $28.15B |
Volume | 949,331 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $150.42 | $251.81 |
52-Week Low | $61.99 | $168.64 |
Typical Hold Time | 24 Days | 59 Days |
Enterprise Value | $3.13B | $28.65B |
Dividend Yield | — | 1.27% |
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Williams-Sonoma (WSM) trades at $241.78, up 0.55% on the day, reflecting strong momentum near its consensus price target of $246.31. The stock exhibits a bullish technical trend, supported by robust fundamentals including a 14.73% net income margin and consistent earnings beats in recent quarters. Recent news highlights market share gains and profitability improvements, with the company raising full-year guidance after strong Q2 2026 results.
The outlook remains positive given WSM's operational efficiency and dividend growth, though risks include housing market sensitivity and competitive pressures. Analyst consensus leans bullish with 32% buy ratings, but high valuation multiples like a P/E of 24.51 warrant caution amid economic uncertainty.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →